Dr Zafar Mirza said today (Jun 21) that Drug Regulatory Authority of Pakistan (DRAP) is taking all the steps to guarantee the accessibility of remdesivir for the patients of Coronavirus.
According to the details, Special Assistant to the Prime Minister on Health Dr Zafar Mirza said that DRAP will make sure the availability of remdesivir for coronavirus patients.
Dr Mrzia said that DRAP has issued import and registration letters to the producers to ensure the availability of remdesivir for coronavirus patients, particularly during emergencies.
He further said that US Food and Drug Association (FDA) had approved the usage of remdesivir for the treatment of COVID-19.
Dr Zafar also said that that the regulatory body has issued licenses to two importers and 14 local manufacturers amid this emergency situation in the country.
The spokesperson added that meetings of the Emergency Registration Board and the Drug Pricing Committee have also been called in the coming days to ensure the availability of injections and to propose the pricing of the drug to the Cabinet.
Dr Zafar added that added the National Command and Control Centre (NOCC) along with DRAP considered the usage of remdesivir after the US, Japan, UK and Europe approved the usage of the drug after successful trials.